Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Combinatorial Drug Therapy for Glioblastoma Multiforme
EF 2014-15
Résumé
Glioblastoma (GBM) is the most prevalent and aggressive form of brain tumours. Primary brain tumours occur in 8 out of 100,000 Canadians. Unfortunately, even with treatment that includes surgery, chemotherapy and radiotherapy, the median survival is only a year. These tumours are able to continuously grow and spread due to a subpopulation of cancer cells, known as cancer stem cells. Even with the current treatments, GBM patients have a dismal prognosis. It is evident that new treatments are needed to improve GBM patient outcomes.
The Weiss group has a large set of brain tumour initiating cell (BTIC) lines, which were isolated from the tumours of over 100 GBM patients. The cell lines reflect the key features of the disease and generate human-like tumours in mouse models, making them a useful tool to study the disease and for drug testing. The objective of this proposal is to use these BTIC lines to investigate whether therapies combining multiple drugs, might be an effective strategy for GBM. Through combinatorial drug therapy, we expect to increase tumour cells killing while reducing the likelihood of drug resistance. Perhaps we can achieve additive or synergistic effects when we co-administer drugs that work by different molecular mechanisms.
We propose that the use of two currently available drugs in combination will be able to effectively inhibit BTIC growth in cell culture as well as in a mouse model and may in the future become a strategy for GBM therapy in the clinic.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331367
Name
Jensen Katharine V
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Combinatorial Drug Therapy for Glioblastoma Multiforme
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Tumor Initiating Cells; Cancer; Combinatorial Drug Therapy; Egfr Signalling; Glioblastoma Multiforme; Jak/Stat Signalling; Molecular Therapeutics
Abstract
Glioblastoma (GBM) is the most prevalent and aggressive form of brain tumours. Primary brain tumours occur in 8 out of 100,000 Canadians. Unfortunately, even with treatment that includes surgery, chemotherapy and radiotherapy, the median survival is only a year. These tumours are able to continuously grow and spread due to a subpopulation of cancer cells, known as cancer stem cells. Even with the current treatments, GBM patients have a dismal prognosis. It is evident that new treatments are needed to improve GBM patient outcomes.
The Weiss group has a large set of brain tumour initiating cell (BTIC) lines, which were isolated from the tumours of over 100 GBM patients. The cell lines reflect the key features of the disease and generate human-like tumours in mouse models, making them a useful tool to study the disease and for drug testing. The objective of this proposal is to use these BTIC lines to investigate whether therapies combining multiple drugs, might be an effective strategy for GBM. Through combinatorial drug therapy, we expect to increase tumour cells killing while reducing the likelihood of drug resistance. Perhaps we can achieve additive or synergistic effects when we co-administer drugs that work by different molecular mechanisms.
We propose that the use of two currently available drugs in combination will be able to effectively inhibit BTIC growth in cell culture as well as in a mouse model and may in the future become a strategy for GBM therapy in the clinic.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jensen, Katharine V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~